Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$21.2b

Incyte Past Earnings Performance

Past criteria checks 6/6

Incyte has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 22.4% annually. Revenues have been growing at an average rate of 12% per year. Incyte's return on equity is 25.6%, and it has net margins of 24.7%.

Key information

10.15%

Earnings growth rate

12.61%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate11.98%
Return on equity25.55%
Net Margin24.69%
Last Earnings Update30 Sep 2025

Recent past performance updates

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06
Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Recent updates

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 31
Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio

Oct 28

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14
Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06
Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

Apr 30
Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Mar 18

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 11

Incyte: Multiple Drug Launches Bode Well For Future Growth

Jan 11

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31
User avatar

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

Incyte: The Worst Has Been Avoided

Jun 16

Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)

Apr 26

Revenue & Expenses Breakdown

How Incyte makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:INCY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 254,8131,1891,329161
30 Jun 254,5858711,309161
31 Mar 254,413211,264161
31 Dec 244,241331,239161
30 Sep 244,076321,186127
30 Jun 243,857971,145127
31 Mar 243,7687451,143164
31 Dec 233,6965981,159127
30 Sep 233,6094251,1380
30 Jun 233,5133661,1360
31 Mar 233,4703241,1050
31 Dec 223,395341999113
30 Sep 223,3318769540
30 Jun 223,3209458790
31 Mar 223,1159337960
31 Dec 212,9869497410
30 Sep 212,9135356820
30 Jun 212,7213386120
31 Mar 212,7034785610
31 Dec 202,667-2965180
30 Sep 202,457-3354870
30 Jun 202,388-1914690
31 Mar 202,229-3764570
31 Dec 192,1594474690
30 Sep 192,1084054410
30 Jun 192,0063064350
31 Mar 191,9972534370
31 Dec 181,8821094350
30 Sep 181,798-1094240
30 Jun 181,729-1024190
31 Mar 181,534-1674010
31 Dec 171,536-3133670
30 Sep 171,419-1553630
30 Jun 171,306-1543480
31 Mar 171,226-1073240
31 Dec 161,1061043020
30 Sep 161,0231512600
30 Jun 16941742310
31 Mar 16858492160
31 Dec 1575471970
30 Sep 15634-861930
30 Jun 15644131840
31 Mar 15581-331740
31 Dec 14511-481660

Quality Earnings: INCY has high quality earnings.

Growing Profit Margin: INCY's current net profit margins (24.7%) are higher than last year (0.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: INCY has become profitable over the past 5 years, growing earnings by 10.2% per year.

Accelerating Growth: INCY's earnings growth over the past year (3559.2%) exceeds its 5-year average (10.2% per year).

Earnings vs Industry: INCY earnings growth over the past year (3559.2%) exceeded the Biotechs industry 52.4%.

Return on Equity

High ROE: INCY's Return on Equity (25.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/12 14:51
End of Day Share Price 2025/11/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 51 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ying HuangBarclays